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Abstract Intratumor heterogeneity—heterogeneity of
cancer cells within a single tumor—is considered one of
the most problematic factors of treatment. Genetic heter-
ogeneity, such as in somatic mutations and chromosome
aberrations, is a common characteristic of human solid
tumors and is probably the basis of biological heteroge-
neity. Using mutations in APC, TP53 and KRAS as markers
to identify distinct colorectal cancer subpopulations, we
analyzed a total of 42 primary colorectal cancer tissues and
six paired liver metastases with multipoint microsampling,
which enabled analysis of mutation patterns and allelic
imbalances with a resolution of 0.01 mm
2 (about 200
cells). There was usually more than one subpopulation in
each primary tumor. Only two of 15 (13.3%) cases with
three gene mutations and eight of 27 (29.6%) cases with
two gene mutations had a single subpopulation. Cells
with mutations in all of the examined genes usually con-
stituted the major population. Multipoint microsampling of
six primary and metastatic tumor pairs revealed that the
majority of discrepancies in mutation patterns found with
the bulk tissue analysis were due to loss of subpopulations
in the metastatic tissues. In addition, multipoint micro-
sampling uncovered substantial changes in subpopulations
that were not detected with bulk tissue analysis. Speciﬁ-
cally, the proportion of KRAS mutation-negative subpop-
ulations increased in the metastatic tumors of four cases.
Because KRAS mutation status is linked to cetuximab/pa-
nitumumab efﬁcacy, subpopulation dynamics could lead to
differences in response to cetuximab/panitumumab in pri-
mary versus metastatic tumors.
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Introduction
Intratumor heterogeneity, which is the heterogeneity of
cancer cells within a single tumor, is considered one of the
most problematic factors of treatment. During anti-cancer
therapy,theinitialregressionofthetumoreventuallyleadsto
the outgrowth of drug-resistant cells. Resistant cells likely
existinaheterogeneousprimarycancercellpopulationrather
than evolve from it. A recently emerging topic related to
heterogeneity is the cancer stem cell (CSC) hypothesis [1],
which assumes that only a fraction of cancer cells have the
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hypothesis claims that currently available drugs are not
effective because they target the total cancer cell population.
In addition to the heterogeneity of biological features
presented by CSC, genetic heterogeneity, such as in
somatic mutations and chromosome aberrations, is a
common characteristic of human solid tumors and is
probably the basis of biological heterogeneity. A number of
studies have described genetic heterogeneity [2–11].
Although these studies have demonstrated that cancer cell
subpopulations with different mutation patterns are present
in most solid tumors, there were several technical limita-
tions. In particular, these studies did not use laser micro-
dissection, which is now a standard technique, and they had
a relatively high threshold of detection, which may have
hampered the detection of rare clones.
Genetic heterogeneity within primary tumors is a single
aspect of tumor heterogeneity. Although tumors develop at
one site, some cancer cells leave the primary tumor and
develop metastases at distant sites. Because metastases
account for the majority of cancer-related deaths, under-
standing the underlying mechanism of their development is
extremely important. Analysis of genetic heterogeneity,
such as in somatic mutations, may help clarify the issue.
Although intratumor heterogeneity has been intensely
studied, the question of heterogeneity within metastases
remains unexplored [12].
Colorectal cancer is one of the most common and well-
studied cancer types. Because somatic mutations in the
APC, KRAS and TP53 genes have been established as
‘‘drivers’’ for colorectal carcinogenesis [13], we chose these
genes as markers to identify cancer cell subpopulations. We
analyzed a total of 42 primary colorectal cancer tissues and
6 paired metastatic tissues with multipoint microsampling
[11, 14], which is our proprietary technical approach for
analyzing intratumor genetic heterogeneity. Multipoint
microsampling enables analysis of mutation patterns and
allelic imbalance with a resolution of 0.01 mm
2 (about 200
cells). We examined the prevalence of intratumor genetic
heterogeneity in primary tumors and the dynamics of cancer
cell subpopulations in primary and metastatic tumors.
Materials and methods
Samples
In a previous study, a total of 86 bulk primary colorectal
cancertissuesfromourtumortissuebankwereexaminedfor
mutations in the APC, KRAS and TP53 genes. DNA was
extracted from frozen bulk tumor tissues using the QIAamp
DNA Micro Kit (Qiagen, Hilden, Germany), and the coding
regions of APC, KRAS and TP53 were examined for
mutationsusingHigh-ResolutionMeltingonaLightScanner
(Idaho Technology, Salt Lake City, UT, USA). Samples
with aberrant melting curves were analyzed using direct
sequencing with the BigDye Terminator Cycle Sequencing
Kit (ver. 3.1, Applied Biosystems, Carlsbad, CA, USA) on
an ABI PRISM 3730 (Applied Biosystems). Cases with a
single mutation, in which cells with no mutation were the
only heterogeneous subpopulation, were excluded because
such a subpopulation was difﬁcult to distinguish from nor-
mal epithelial cells. Forty-two primary colorectal cancer
tissues were included in the present study: 15 tumor tissues
with mutations in all three genes (i.e., APC, KRAS and TP53
genes) and 27 tumors with only two mutated genes. The
details of the mutations in these tumors are listed in Table
S1. In addition, 6liver metastatic tissues from the cases with
mutations in all three genes were included in the study. The
present study was approved by the Ethical Committee of the
Osaka Medical Center for Cancer and Cardiovascular Dis-
eases, and informed consent was obtained from all patients.
Multipoint microsampling
For the analysis of intratumor heterogeneity, 40-lm-thick
sections from frozen cancer tissues were prepared on a
Leica CM1900 cryostat (Leica Microsystems, Wetzlar,
Germany) and stained with Mayer’s hematoxylin (Wako,
Osaka, Japan). Forty to ﬁfty small areas (100 9 100 lm)
containing only tumor cells were microdissected from each
sample. Microdissection was performed using the Leica AS
LMD system (Leica Microsystems). The sampling was
randomized, but we avoided repeated sampling from the
same region. Genomic DNA was extracted using the
prepGEM Kit (ZyGEM, Hamilton, New Zealand),
according to the manufacturer’s protocol, and a 20-ll DNA
mixture was prepared from each sample.
PCR ampliﬁcation and SNaPshot assay
Foreachcase,theDNAfragmentsthatwerefoundtocontain
mutations in bulk tissue analysis were simultaneously
ampliﬁed using multiplex PCR on a GeneAmp PCR System
9700 (Applied Biosystems). The PCR was performed in a
10-ll reaction volume including 5 ll DNA (approximately
250 pg), 19 PCR buffer (Applied Biosystems), 2 mM
MgCl2, 200 lM of each dNTP, 0.2 lM of each primer
(Table S2) and 1 U AmpliTaqGold polymerase (Applied
Biosystems). The cycling conditions consisted of an initial
denaturation step at 94C for 5 min, 40 cycles of denaturing
at 94C for 30 s, annealingat 54–56C for 30 s, extension at
72C for 40 s and a ﬁnal synthesis at 72C for 5 min.
The mutation status was quantitatively determined using
the SNaPshot assay. Each primer was designed to bind to a
complementary template immediately adjacent to the
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123mutation site. The reaction was carried out in the presence
of ﬂuorescently labeled ddNTPs, and DNA polymerase was
used to extend the primer by one nucleotide (adding a
single ddNTP to its 30 end). The following ﬂuorescent
dyes were used for the dideoxynucleotides: A, dR6G; C,
dTAMRA; G, dR110; and T, dROX.
The PCR fragments were prepared for primer extension
by incubating a mixture containing 7.5 ll PCR product,
0.5 U shrimp alkaline phosphatase (SAP) (TaKaRa, Otsu,
Japan) and 1 U exonuclease I (TaKaRa) in a ﬁnal volume
of 10 lla t3 7 C for 40 min, which was followed by
inactivation of the enzymes at 80C for 20 min. Primer
extension was carried out in a 5-ll reaction, which con-
tained 2 ll treated PCR product, 2.5 ll ABI Prism SNaP-
shot Multiplex Ready Reaction Mix (Applied Biosystems)
and 0.5 ll extension primer mix (0.2 lM of each primer).
The primer sequences are shown in Table S2. The cycling
conditions, which were carried out according to the man-
ufacturer’s protocol, included 25 cycles of denaturation at
96C for 10 s, annealing at 50C for 5 s and extension at
60C for 30 s. To remove the unincorporated ddNTPs, 5 ll
of the SNaPshot products was incubated for 40 min at 37C
with 0.5 U SAP (TaKaRa) in a ﬁnal volume of 6 ll, and the
enzyme was inactivated as described above. A 1-ll aliquot
of the treated SNaPshot reaction was denatured in 9 ll
distilled water in the presence of GeneScan 120 LIZ Size
Standard (Applied Biosystems) for 5 min at 95C and
analyzed on an ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems). Fragment analysis was performed
with Gene Mapper Software v4.0 (Applied Biosystems).
Data analysis
The mutation status of each area was determined by calcu-
lating the mutant allele ratio (DM) for each gene using the
following equation: DM = M/(M ? N), where M is the
mutant allele peak height and N is the normal peak height.
The reproducibility of ampliﬁcation and the SNaPshot assay
was conﬁrmed in our previous experiments [14]. In most
cases of mutant allele loss, the corresponding peak height
(M) was zero. However, there were several areas with
residual peaks where we set the threshold for DM at 0.05.
Results
Intratumor heterogeneity of primary colorectal cancers
In a previous study, we established a method called mul-
tipoint microsampling to characterize genetic heterogeneity
in colorectal cancer using laser microdissection [11, 14].
This method has two characteristics: (1) a sample size
small enough to keep contamination from other cell pop-
ulations to a minimum, but large enough to ensure unbi-
ased ampliﬁcation, and (2) a high enough sample number
(*50) to obtain reproducible results from minor
Fig. 1 An example of
intratumor heterogeneity. a A
microscopic view of a colorectal
cancer tissue section with black
circles indicating the
microdissected areas (1–5).
b Electropherograms of the
SNaPshot assay. The ﬁrst two
peaks represent the mutation
status of APC (C[G), and the
second two peaks represent the
mutation status of KRAS (G[A).
The blue peak is a fragment
ampliﬁed with ddG, the black
peak is a fragment ampliﬁed
with ddC and the green peak is a
fragment ampliﬁed with ddA.
c Graphic representation of the
SNaPshot results. The mutant
allele ratio (DM) of APC is
plotted on the x-axis, and the
DMo fKRAS is plotted on the
y-axis
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123Table 1 Summary of the genotypes in the 42 primary tumors
Case Clinical stage Samples/tumor Clone Genotype Areas % AIH
b-APC AIH
b-KRAS AIH
b-TP53
APC mut
a KRAS mut
a TP53 mut
a
1I V 4 2 A -- ? 3 7,1 ?? ?
B ?- ? 1 2,4
C ?? ? 38 90,5
3I I 4 8 A -? ? 2 4,2 ?? ?
B ?? ? 46 95,8
11 III 41 A ?- - 7 17,1 ?? -
B ?? - 4 9,8
C ?? ? 30 73,2
19 III 45 A -? ? 2 4,4 ?? ?
B ?? ? 43 95,6
24 II 49 A ?- ? 2 4,1 ?? ?
B ?? ? 47 95,9
33 IV 48 A ?- - 21 43,8 -? ?
B ?? - 9 18,8
C ?? ? 18 37,5
41 III 40 A -- ? 7 17,5 ?? ?
B -? ? 1 2,5
C ?? ? 32 80
49
c IV 40 A ?/?? ? 40 100 ?? -
51 IV 42 A -- ? 1 2,4 ?? ?
B ?- ? 2 4,8
C ?? ? 39 92,9
65 IV 49 A ?- - 2 4,1 ?? ?
B ?- ? 2 4,1
C ?? ? 45 91,8
74 I 41 A ?? ? 41 100 ?- ?
81 IV 42 A ?? - 4 9,5 ?? ?
B ?? ? 38 90,5
82 IV 48 A ?- ? 1 2,1 ?? ?
B -- ? 3 6,3
C -? ? 41 85,4
D ?? ? 1 2,1
83 IV 45 A ?? - 4 8,9 ?? ?
B ?? ? 41 91,1
85 IV 44 A ?- ? 1 2,3 ?? ?
B -? - 2 4,5
C -- ? 1 2,3
D -? ? 35 79,5
E ?? ? 5 11,4
4 III 44 A ?? - 44 100 ?? ND
6I I 4 0 A ?? - 40 100 -- ND
12 III 49 A ?- - 13 26,5 ?? ND
B ?? - 36 73,5
13 II 45 A -? - 1 2,2 ?? ND
B ?? - 44 97,8
430 Clin Exp Metastasis (2011) 28:427–435
123Table 1 continued
Case Clinical stage Samples/tumor Clone Genotype Areas % AIH
b-APC AIH
b-KRAS AIH
b-TP53
APC mut
a KRAS mut
a TP53 mut
a
18 III 46 A ?- - 1 2,2 ?? ND
B ?? - 45 97,8
21 II 50 A -? - 24 ?- ND
B ?? - 48 96
57 III 50 A ?? - 50 100 -- ND
8
c III 50 A ?/?- - 36 ? ND ?
B -- ? 91 8
C ?- ? 81 6
D ?/?- ? 30 60
9I V 5 0 A ?- ? 50 100 ? ND -
17 III 47 A ?- - 1 2,1 ? ND ?
B -- ? 3 6,4
C ?- ? 43 91,5
20 II 42 A ?- - 4 9,5 ? ND ?
B -- ? 3 7,1
C ?- ? 35 83,3
28 II 50 A ?- ? 50 100 - ND ?
36 I 50 A ?- ? 50 100 ? ND ?
39 III 50 A -- ? 38 76 - ND ?
B ?- ? 12 24
43
c I5 0A ?- - 24 ? ND ?
B ?- ? 24
C ?/?- ? 46 92
46
c II 50 A ?- - 51 0 ? ND ?
B ?- ? /? 45 90
48 III 41 A -- ? 2 4,9 ? ND -
B ?- ? 39 95,1
63
c II 50 A ?/?- - 12 ? ND ?
B ?/?- ? 49 98
66 I 50 A ?- ? 50 100 ? ND ?
67 III 49 A -- ? 18 36,7 ? ND ?
B ?- ? 31 63,3
70 III 44 A ?- - 2 4,5 ? ND ?
B ?- ? 42 95,5
75 III 40 A ?- - 5 12,5 ? ND ?
B ?- ? 35 87,5
76 II 40 A ?- - 25 ? ND ?
B -- ? 7 17,5
C ?- ? 31 77,5
10 II 49 A -- ? 5 10,2 ND ?-
B -? ? 44 89,8
26 II 42 A -? - 4 9,5 ND ??
B -- ? 9 21,4
C -? ? 29 69
47 III 50 A -? ? 50 100 ND -?
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123populations. To detect mutations, we used the SNaPshot
assay, which is a quantitative primer extension assay that
yields ratios of mutated and normal alleles.
All 42 samples were subjected to multipoint micro-
sampling. Figure 1 shows a microscopic image of a tumor
tissue section from case 12 (Fig. 1a), an electropherogram
of the SNaPshot assay (Fig. 1b) and a graphical presenta-
tion of the mutant allele ratios (DM) of APC and KRAS
(Fig. 1c). Although all ﬁve regions in Fig. 1a contained
cells with mutations in APC, not all of the regions carried
mutations in KRAS; there was only one peak (ddG) for the
KRAS allele in region 2 (Fig. 1b, c).
The mutation statuses of all samples taken from primary
tumor tissues are summarized in Table 1. Representative
resultsofareasfromprimarycolorectalcancertissuesplotted
inthreedimensionswerecreatedusingtheDMvaluesofAPC,
KRAS and TP53, and 2-D plots were made for the samples
with two mutated genes. These results are shown in Fig. S1.
There was usually more than one subpopulation in each
primary tumor. Indeed, only two of 15 (13.3%) cases with
three gene mutations and eight of 27 (29.6%) cases with
two gene mutations exhibited a single subpopulation. In
most heterogeneous tumors, cells with all mutations con-
stituted the major population (Table 1).
Because the SNaPshot assay measures relative levels
of both alleles, we also revealed heterogeneity of allelic
imbalance. Because the standard deviation of the SNaPshot
assaywas0.08[14],caseswherethedatarangeswereover0.32
(±2r) were considered heterogeneous. For example, case 10
showed heterogeneity in the allele ratio of KRAS (DM =
0.0–0.53), but not of TP53 (DM = 0.94–1.0), whereas case 6
did not show heterogeneity for either of the two genes
(DM = 0.46–0.61 for KRAS and 0.85–1.0 for APC)( F i g .S 1 ) .
The status of the heterogeneityof allelic imbalance is shown in
Table 1. The heterogeneity was probably due to a mixture of
two or more cell subpopulations with different allelic ratios.
Comparison of intratumor genetic heterogeneity
between primary and metastatic tumors
Among the 15 primary tumors with the three gene muta-
tions, six cases had corresponding hepatic metastatic
tumors. The details of mutations revealed by bulk tissue
analysis are shown in Table 2. Except for two cases (82
and 85), metastatic tissues carried the same mutations as
the corresponding primary tumors. We compared the
intratumor heterogeneity of the three gene mutations
between primary and metastatic tumors for each case.
Table 3 summarizes the mutation status of subpopulations
in the tissue pairs. The percentages of each subpopulation
in a primary tumor and its paired metastasis are graphically
presented for all six cases in Fig. 2.
Table 1 continued
Case Clinical stage Samples/tumor Clone Genotype Areas % AIH
b-APC AIH
b-KRAS AIH
b-TP53
APC mut
a KRAS mut
a TP53 mut
a
64 I 46 A -? - 23 50 ND ??
B -? ? 23 50
a mut mutations given in Table S1 for each tumor case
b AIH heterogeneity in allelic imbalance
c Cases with two mutations in one gene (case 8, 43, 46, 49, 63). ‘‘?/?’’ means two mutations, ‘‘?’’ one mutation, ‘‘-’’ no mutation in the gene.
For case 8 single mutation in APC is c.3139 G[T; for case 43-c.904 C[T
Table 2 Mutations found by
bulk tissue analysis of six pairs
of primary and metastatic
tumors
a Stop codon
Case Sample APC mutation KRAS mutation TP53 mutation
1 T c.4348 C[T R1450
a c.34 G[T G12C c.818 G[A R273H
M c.4348 C[T R1450
a c.34 G[T G12C c.818 G[A R273H
51 T c.2626 C[T R876
a c.35 G[T G12V c.818 G[A R273H
M c.2626 C[T R876
a c.35 G[T G12V c.818 G[A R273H
81 T c.1690C[T R564
a c.183 A[T Q61H c.524 G[A R175H
M c.1690C[T R564
a c.183 A[T Q61H c.524 G[A R175H
82 T c.2626 C[T R876
a c.34 G[A G12S c.755_63 del 9 bp
M – c.34 G[A G12S c.755_63 del 9 bp
83 T c.4147 insA c.38 G[A G13D c.682 ins 8 bp
M c.4147 insA c.38 G[A G13D c.682 ins 8 bp
85 T c.2626 C[T R876
a c.35 G[T G12V c.733 G[A G245S
M – c.35 G[T G12V c.733 G[A G245S
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123In cases 82 and 85, there were discrepancies of mutation
patterns; both cases lacked APC mutations in metastatic
tumors (Table 2). Indeed, multipoint microsampling
revealed that metastatic tumors lacked subpopulations with
an APC mutation in both cases (i.e., subpopulations A and
D in case 82 and subpopulations A and E in case 85)
(Table 3 and Fig. 2d and f).
Incases51and83,themajorsubpopulationoftheprimary
tumoroccupiedallareasofthemetastatictumor(Fig. 2band
e, respectively). This result suggests that at least mostcancer
cells in the liver metastases were derived from the major
subpopulations of the primary tumors in these two cases. In
othercases,therewasmorethanonesubpopulationwithinthe
metastatic tumor tissue. In all cases, there were no de novo
mutations, which suggests that cells from subpopulations in
the primary tumors moved to the liver. In cases 1, 82 and 85,
the proportions of KRAS mutation-negative subpopulations
increased (Fig. 2a, d and f, respectively). Because both the
primary and metastatic tumors in case 1 were mostly com-
posed of a single major subpopulation, we performed array-
CGH to exclude the possibility that the KRAS mutant allele
wouldbelostbyLOHaftermetastasizing.Notably,therewas
no LOH in the KRAS region (data not shown), which sug-
gests that the mutation-negative subpopulation of the
metastatic tumor was derived from the minor mutation-neg-
ative subpopulation of the primary tumor.
Discussion
Multipoint microsampling offers much higher resolution
than techniques used in similar studies in the literature
[2–11]. Consequently, we found intratumor heterogeneity
in 87% of primary tumors with mutations in three genes
(i.e., APC, KRAS and TP53) and in 70% of tumors with
mutations in two of the three genes. We then compared
mutation statuses between primary and metastatic tumors.
The multipoint microsampling approach revealed that
discrepancies of mutation patterns found by bulk tissue
analysis were due to loss of subpopulations in the meta-
static tissues. In addition, multipoint microsampling
uncovered substantial changes in subpopulations that were
not detected by bulk tissue analysis, such as the increase of
KRAS mutation-negative cells in metastatic tumors.
A recent study of exome sequencing in pancreatic can-
cer reported a similar ﬁnding. Indeed, clonal populations
that give rise to distant metastases were represented in one
of the subpopulations taken from several parts of the
Table 3 Cell populations found in primary tumors and metastases of the patients
Case Clone Genotype Examined
samples/
tumor
Areas in
primary
tumor
b
% Examined
samples/
metastasis
Areas in
metastasis
b
%
APC mut
a KRAS mut
a TP53 mut
a
1 A – – c.818 G[A R273H 42 3 7.1 50 0 0
B c.4348 C[T R1450
c – c.818 G[A R273H 1 2.4 36 72.0
C c.4348 C[T R1450
c c.34 G[T G12C c.818 G[A R273H 38 90.5 14 28.0
51 A – – c.818 G[A R273H 42 1 2.4 50 0 0
B c.2626 C[T R876
c – c.818 G[A R273H 2 4.8 0 0
C c.2626 C[T R876
c c.35 G[T G12V c.818 G[A R273H 39 92.9 50 100.0
81 A c.1690C[T R564
c c.183 A[T Q61H – 42 4 9.5 50 7 14.0
B c.1690C[T R564
c c.183 A[T Q61H c.524 G[A R175H 38 90.5 43 86.0
82 A c.2626 C[T R876
c – c.755_63 del 9 bp 48 1 2.1 49 0 0
B – – c.755_63 del 9 bp 3 6.3 25 51.0
C – c.34 G[A G12S c.755_63 del 9 bp 41 85.4 24 49.0
D c.2626 C[T R876
c c.34 G[A G12S c.755_63 del 9 bp 3 6.3 0 0
83 A c.4147 insA c.38 G[A G13D – 45 4 8.9 50 0 0
B c.4147 insA c.38 G[A G13D c.682 ins 8 bp 41 91.1 50 100.0
85 A c.2626 C[T R876
c – c.733 G[A G245S 44 1 2.3 50 0 0
B – c.35 G[T G12V – 2 4.5 0 0
C – – c.733 G[A G245S 1 2.3 9 18.0
D – c.35 G[T G12V c.733 G[A G245S 35 79.5 41 82.0
E c.2626 C[T R876
c c.35 G[T G12V c.733 G[A G245S 5 11.4 0 0
a mut mutation
b Number of samples with a speciﬁc genotype
c Stop codon
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123primary tumors [15]. This study by Campbell et al. iden-
tiﬁed far more mutations than our study. In addition, the
Campbell et al. study identiﬁed the original parental non-
metastatic clones from which metastatic clones evolved. In
the present study, we used multipoint microsampling,
which has a markedly greater spatial resolution because the
exome sequencing study was based on DNA prepared from
more than 100 million cells. We found that the metastatic
tumors included more than one subpopulation of the pri-
mary tumor in four cases (Fig. 2). In liver metastases,
colorectal cancer cells move to the liver via the portal vein,
which differs from ordinary distant metastases where cells
move through the systemic circulation. The simultaneous
migration of more than one subpopulation might be spe-
ciﬁc to liver metastases of colorectal cancer because of this
anatomical characteristic.
Clinical trials with cetuximab or panitumumab revealed
that patients with wild-type KRAS responded to therapy (up
to 50%), whereas those with tumors exhibiting KRAS
mutations had a low response rate (0–6%) [16–21].
Although the KRAS mutation status is predictive of
cetuximab/panitumumab efﬁcacy, there are cases in which
the response did not match the prediction. Based on a
hypothesis that the heterogeneity of KRAS mutations
between primary and metastatic tumors may be responsible
for this discrepancy, Italiano et al. analyzed 95 pairs of
primary and metastatic tumors. Italiano et al. found that
KRAS was mutated in primary tumors in six cases, but
wild-type KRAS was found in metastatic tumors. In addi-
tion, eight cases showed that KRAS was mutated in meta-
static tumors, but wild-type KRAS was found in primary
tumors [22]. Moreover, Baldus et al. analyzed 20 pairs of a
primary tumor and a distant metastasis, and found hetero-
geneity of the KRAS mutation status in two cases [23].
Heterogeneity between primary and lymph node metasta-
ses was more frequent (31% of cases) than that between
primary and metastatic tumors. Both studies indicated that
the discrepancy of the KRAS mutation status between a
primary tumor and its distant metastasis was likely to be
too rare to account for the discordance between the KRAS
mutation status and cetuximab/panitumumab efﬁcacy. The
results from these two studies, however, were obtained
with analysis of bulk tissues or macrodissection. The
present study demonstrated that there were changes in
proportions of subpopulations that could not be detected by
bulk tissue analysis. Thus, the possibility remains that
heterogeneity of the KRAS mutation status could be the
cause of altered cetuximab/panitumumab efﬁcacy. Our
preliminary study on intratumor heterogeneity of EGFR
mutations in lung cancer suggested that tumors that have
cancer cells with wild-type EGFR exhibited an inferior
response to geﬁtinib [11]. Because molecularly targeted
drugs are becoming the mainstream of adjuvant therapy,
intratumor heterogeneity of target genes might be an
important factor requiring further intensive analysis.
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Fig. 2 Genetic heterogeneity in
six pairs of primary and
metastatic tumor tissues. The
percentages of areas with a
particular mutation status in the
primary tumor (PT) and its
paired metastasis (M) are
graphically presented for each
case. The mutation patterns are:
APC
NKRAS
NTP53
M, yellow;
APC
NKRAS
MTP53
N, light
purple; APC
MKRAS
NTP53
M,
dark blue;
APC
NKRAS
MTP53
M, green;
APC
MKRAS
MTP53
N, light
blue; and APC
MKRAS
MTP53
M,
red (M, mutated gene; N, no
mutation). a Case 1, b case 51,
c case 81, d case 82, e case 83,
and f case 85
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